Electrochemically Activated Salt Solution for Ocular Infections

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for ocular infections, particularly those involving topical antibiotics, face challenges such as antibiotic resistance, allergic reactions to preservatives, and the need for acidic pH which can irritate the eyes and reduce patient compliance.

Innovation Solution

An electrochemically activated salt solution (ECAS) with specific parameters including a total chlorine content of 1-500 mg/l, chloride content of 2-8 g/l, redox potential of +150 to +1,350 mV, osmolality of 20-800 mOsm/kg, and a pH value of 6.0-7.8, along with the inclusion of salts of boric acid and/or phosphoric acid, is developed for treating eye infections.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If topical antibiotics are used to treat ocular infections, then antimicrobial efficacy is improved, but antibiotic resistance and allergic reactions occur

Engineering Contradiction:
Improveantimicrobial efficacyVSAvoidantibiotic resistance and allergic reactions
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters of the treatment solution by using electrochemically activated salt solution with specific pH (6.0-7.8), redox potential (+150 to +1,350 mV), and chlorine content (1-500 mg/l) to achieve antimicrobial efficacy without the harmful effects of traditional antibiotics

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent converts the potentially harmful high redox potential into a beneficial antimicrobial mechanism that destroys microbial cells through oxidative stress, while the physiological pH converts the previously harmful acidic environment into a patient-friendly formulation

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If acidic pH is used in ophthalmic preparations, then antimicrobial activity is improved, but eye irritation occurs and patient compliance decreases

Engineering Contradiction:
Improveantimicrobial activityVSAvoideye irritation
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pH parameter from traditionally acidic (pH 3-5) to physiological range (pH 6.0-7.8), eliminating eye irritation while maintaining antimicrobial activity through the combined effect of redox potential and chlorine content

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent introduces redox potential as an intermediary mechanism that enables antimicrobial activity at physiological pH, acting as a mediator between the salt solution and microbial cells through oxidative damage

Inventive Principle:
Principle #24Intermediary (Mediator)

3Stability of the object's composition

If preservatives are added to multi-dose ophthalmic preparations, then stability is improved, but allergic reactions occur

Engineering Contradiction:
Improvepreparation stabilityVSAvoidallergic reactions to preservatives
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent makes the salt solution itself self-preserving through its inherent antimicrobial properties generated by electrochemical activation, eliminating the need for external preservatives that cause allergic reactions

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The patent converts the previously harmful need for preservatives into a benefit by using the electrochemically generated hypochlorous acid and other reactive species as natural preservatives that are effective against microbes but safe for human tissue

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The ECAS effectively treats eye infections such as conjunctivitis and keratitis without the need for additional therapeutically active agents or preservatives, demonstrating strong antimicrobial activity and improved stability over time.

Implementation Method 1

The ECAS effectively treats eye infections such as conjunctivitis and keratitis without the need for additional therapeutically active agents or preservatives, demonstrating strong antimicrobial activity

Methodology Applied
Scientific EffectOxidative stress: Oxidation

Implementation Method 2

Electrochemically activated salt solutions are usually obtained by electrolysis of sodium chloride solutions

Methodology Applied
Scientific EffectElectrolysis: Electrolysis

Data Source

PatentEP3820568B1Electrochemically activated salt solution for use in the treatment of infections
Publication Date: 2025.04.16 AZAD PHARMA
  • EP3820568B1 patent drawingFigure 1~2
  • EP3820568B1 patent drawingFigure 3~4
  • EP3820568B1 patent drawingFigure 5~6

AI summary

The present application refers to an electrochemically activated salt solution (EGAS), its production, and its use for treating infections.